Large Outflow of Money Witnessed in Teva Pharmaceutical Industries Limited

Teva Pharmaceutical Industries Limited (TEVA) : The total money flow in Teva Pharmaceutical Industries Limited (TEVA) was negative ($8.66 million), which signals selling by the traders on Tuesdays session. They trimmed their holdings by selling the stock on downticks to the tune of $46.06 million. In comparison, the inflow of money into the stock on upticks was $37.4 million. The uptick to downtick ratio was 0.81. Similarly, the block trades show selling by large traders on strength. The value of stocks sold down on downtick was $15.67 million. The value of transactions on uptick was $7 million. The negative money flow of ($8.67 million) confirms the selling in Teva Pharmaceutical Industries Limited (TEVA) on strength. The uptick to downtick ratio of block trades was 0.45. Teva Pharmaceutical Industries Limited (TEVA) gained $0.04 at $50.93, a gain of 0.08% over the previous days close. However, the stock registered 1.76% in the week.

Teva

The company Insiders own 7.1% of Teva Pharmaceutical Industries Limited shares according to the proxy statements. Institutional Investors own 64.05% of Teva Pharmaceutical Industries Limited shares.

Shares of Teva Pharmaceutical Industries Limited appreciated by 4.98% during the last five trading days but lost 1.04% on a 4-week basis. Teva Pharmaceutical Industries Limited has dropped 3.86% during the last 3-month period . Year-to-Date the stock performance stands at -19.06%.

Teva Pharmaceutical Industries Limited (NYSE:TEVA): stock turned positive on Tuesday. Though the stock opened at $51.25, the bulls momentum made the stock top out at $52.92 level for the day. The stock recorded a low of $50.83 and closed the trading day at $52.46, in the green by 3.00%. The total traded volume for the day was 8,941,905. The stock had closed at $50.93 in the previous days trading.

Teva Pharmaceutical Industries Limited (Teva) is a global pharmaceutical and drug company. The Companys generic products cover almost every major therapeutic area. The Company operates its business in two segments: Generic medicines, which manufactures and sells generic pharmaceutical products in several dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams, and Specialty medicines, which delivers solutions to patients and providers via medicines, devices and services. Its Central Nervous System (CNS) portfolio includes Copaxone, Azilect and Nuvigil. Its main respiratory medicines include ProAir hydrofluoroalkane, QVAR and Duoresp Spiromax. Its oncology portfolio includes Treanda, Trisenox, Granix Synribo, Lonquex, Tevagrastim/Ratiograstim, Myocet, Trisenox and Eporatio. Its womens health portfolio includes ParaGard, Plan B One-Step OTC/Rx (levonorgestrel) and Zoely.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.